Trial · NCT00798317
Adverse events90
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
61 to 80 of 90
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Sick sinus syndrome | Cardiac disorders | Ocriplasmin 125ug | 1 | 245 | 1 |
| serious | Sick sinus syndrome | Cardiac disorders | Placebo | 0 | 81 | 0 |
| serious | Brain cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Ocriplasmin 125ug | 1 | 245 | 1 |
| serious | Brain cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 81 | 0 |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Ocriplasmin 125ug | 1 | 245 | 1 |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 81 | 0 |
| serious | Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Ocriplasmin 125ug | 1 | 245 | 1 |
| serious | Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 81 | 0 |
| serious | Gastrointestinal haemorrahge | Gastrointestinal disorders | Ocriplasmin 125ug | 1 | 245 | 1 |
| serious | Gastrointestinal haemorrahge | Gastrointestinal disorders | Placebo | 0 | 81 | 0 |
| serious | Pancreatitis | Gastrointestinal disorders | Ocriplasmin 125ug | 1 | 245 | 1 |
| serious | Pancreatitis | Gastrointestinal disorders | Placebo | 0 | 81 | 0 |
| serious | Diverticulitis | Infections and infestations | Ocriplasmin 125ug | 1 | 245 | 1 |
| serious | Diverticulitis | Infections and infestations | Placebo | 0 | 81 | 0 |
| serious | Penumonia | Infections and infestations | Ocriplasmin 125ug | 1 | 245 | 1 |
| serious | Penumonia | Infections and infestations | Placebo | 0 | 81 | 0 |
| serious | Arthritis | Musculoskeletal and connective tissue disorders | Ocriplasmin 125ug | 1 | 245 | 1 |
| serious | Arthritis | Musculoskeletal and connective tissue disorders | Placebo | 0 | 81 | 0 |
| serious | Reumathoid arthritis | Musculoskeletal and connective tissue disorders | Ocriplasmin 125ug | 1 | 245 | 1 |
| serious | Reumathoid arthritis | Musculoskeletal and connective tissue disorders | Placebo | 0 | 81 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00798317/events?page=4